1. Home
  2. HTD vs PHAT Comparison

HTD vs PHAT Comparison

Compare HTD & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HTD
  • PHAT
  • Stock Information
  • Founded
  • HTD 2004
  • PHAT 2018
  • Country
  • HTD United States
  • PHAT United States
  • Employees
  • HTD N/A
  • PHAT N/A
  • Industry
  • HTD Finance Companies
  • PHAT Biotechnology: Pharmaceutical Preparations
  • Sector
  • HTD Finance
  • PHAT Health Care
  • Exchange
  • HTD Nasdaq
  • PHAT Nasdaq
  • Market Cap
  • HTD 863.8M
  • PHAT 942.6M
  • IPO Year
  • HTD N/A
  • PHAT 2019
  • Fundamental
  • Price
  • HTD $24.77
  • PHAT $14.66
  • Analyst Decision
  • HTD
  • PHAT Strong Buy
  • Analyst Count
  • HTD 0
  • PHAT 5
  • Target Price
  • HTD N/A
  • PHAT $17.60
  • AVG Volume (30 Days)
  • HTD 92.3K
  • PHAT 968.0K
  • Earning Date
  • HTD 01-01-0001
  • PHAT 10-30-2025
  • Dividend Yield
  • HTD 8.59%
  • PHAT N/A
  • EPS Growth
  • HTD N/A
  • PHAT N/A
  • EPS
  • HTD N/A
  • PHAT N/A
  • Revenue
  • HTD N/A
  • PHAT $147,190,000.00
  • Revenue This Year
  • HTD N/A
  • PHAT $218.38
  • Revenue Next Year
  • HTD N/A
  • PHAT $87.14
  • P/E Ratio
  • HTD N/A
  • PHAT N/A
  • Revenue Growth
  • HTD N/A
  • PHAT 460.30
  • 52 Week Low
  • HTD $16.17
  • PHAT $2.21
  • 52 Week High
  • HTD $22.13
  • PHAT $16.08
  • Technical
  • Relative Strength Index (RSI)
  • HTD 48.11
  • PHAT 67.17
  • Support Level
  • HTD $24.70
  • PHAT $13.79
  • Resistance Level
  • HTD $25.21
  • PHAT $14.22
  • Average True Range (ATR)
  • HTD 0.27
  • PHAT 0.99
  • MACD
  • HTD 0.01
  • PHAT 0.06
  • Stochastic Oscillator
  • HTD 36.67
  • PHAT 63.13

About HTD John Hancock Tax Advantaged Dividend Income Fund of Beneficial Interest

John Hancock Tax-advantaged Div Inc Fd is a closed-end, diversified management investment company. Its investment objective is to provide a high after-tax total return from dividend income and capital appreciation. The fund's portfolio composition consists of common stocks, preferred securities, corporate bonds, convertible bonds, and short-term investments. Its sector composition comprises utilities, financials, energy, telecommunication services, industrials, healthcare, real estate, consumer discretionary and short-term investments.

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Share on Social Networks: